{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-028386","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.061047+00:00","generated_at":"2026-05-15T01:36:09.363511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"confidence":"high","headline":"Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028","bullets":["Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.","R&D expenses $17.9M (up 69% YoY) on CR-001/CR-002 development; G&A $7.9M (up 119% YoY).","Cash $189.2M as of March 31, 2026; expected to fund operations into 2028.","CR-001 ASCEND trial enrollment ongoing; proof-of-concept data expected Q1 2027.","CR-002 IND submission on track for mid-2026; clinic entry H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-028386","json":"https://secwatch.observer/filing/0001628280-26-028386.json","markdown":"https://secwatch.observer/filing/0001628280-26-028386.md","text":"https://secwatch.observer/filing/0001628280-26-028386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/0001628280-26-028386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026028386/cbio-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:36:09.363511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}